Literature DB >> 15886799

Effect of oral contraceptives on the anticoagulant activity of protein S in plasma.

Rory R Koenen1, M Christella, L G D Thomassen, Guido Tans, Jan Rosing, Tilman M Hackeng.   

Abstract

We determined anticoagulant parameters that depend on protein S function in plasma, i.e. the APC-independent anticoagulant activity of protein S (expressed as pSR) and APC resistance determined with thrombin generation-based tests (expressed as APCsr) as well as plasma levels of total and free protein S and prothrombin in men, women not using oral contraceptives (OC), and in women using second or third generation OC. Thrombin generation in the APC resistance assays was initiated either with factor Xa (Xa-APCsr) or tissue factor (TF-APCsr). The APC-independent anticoagulant activity of protein S was highest in men (pSR=1.69) and gradually decreased from women not using OC (pSR=1.49) via women using second generation (pSR=1.35) to women using third generation OC (pSR=1.27). The pSR correlated inversely with nAPCsr determined with the tissue factor-based APC resistance test (TF-APCsr) but not with nAPCsr determined with the factor Xa-based assay (Xa-APCsr). Multiple linear regression analysis in which sex, OC use, and protein S and prothrombin levels were included as independent variables and the pSR, TF-APCsr or Xa-APCsr as dependent variables indicated that plasma protein S levels poorly predict the pSR and the TF-APCsr, but are the main determinant of the Xa-APCsr. This indicates that OC use alters the expression of protein S activity. This phenomenon can be caused by differences in modulation of the activity of protein S by other plasma proteins that change during OC use or by OC-induced changes in the protein S molecule that impair its anticoagulant activity. Functional impairment of protein S as a result of hormonal influence may, at least in part, contribute to the thrombotic risk of OC users.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886799     DOI: 10.1160/TH04-11-0762

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

2.  Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.

Authors:  Elisabetta Castoldi; Lisbeth F A Maurissen; Daniela Tormene; Luca Spiezia; Sabrina Gavasso; Claudia Radu; Tilman M Hackeng; Jan Rosing; Paolo Simioni
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 3.  Estrogen and thrombosis: A bench to bedside review.

Authors:  Mouhamed Yazan Abou-Ismail; Divyaswathi Citla Sridhar; Lalitha Nayak
Journal:  Thromb Res       Date:  2020-05-11       Impact factor: 3.944

4.  Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.

Authors:  Pansakorn Tanratana; Paul Ellery; Pamela Westmark; Alan E Mast; John P Sheehan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-02       Impact factor: 8.311

5.  Extracellular Vesicles from Steatotic Hepatocytes Provoke Pro-Fibrotic Responses in Cultured Stellate Cells.

Authors:  Maria Teresa Koenen; Elisa Fabiana Brandt; Dawid Marcin Kaczor; Tim Caspers; Alexandra Catharina Anna Heinzmann; Petra Fischer; Daniel Heinrichs; Theresa Hildegard Wirtz; Christian Trautwein; Rory R Koenen; Marie-Luise Berres
Journal:  Biomolecules       Date:  2022-05-13

Review 6.  Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories.

Authors:  A Magnette; M Chatelain; B Chatelain; H Ten Cate; F Mullier
Journal:  Thromb J       Date:  2016-12-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.